Papillary Thyroid Cancer News and Research

RSS

Papillary Thyroid Cancer is cancer that forms in follicular cells in the thyroid and grows in small finger-like shapes. It grows slowly, is more common in women than in men, and often occurs before age 45. It is the most common type of thyroid cancer.

ATA announces research grants to support projects proposed by young researchers

The American Thyroid Association is pleased to announce that grants have been awarded to support projects proposed by leading young researchers. Three of these projects involve the genetic analysis of thyroid tumors carrying the BRAFV600E mutation, which is associated with the development of some forms of thyroid cancer and increased risk for distant metastases, more advanced disease, and higher mortality.

13 Oct 2015

Paediatric primary hyperparathyroidism in rarely a familial disorder

Researchers report that primary hyperparathyroidism in children and adolescents is usually caused by a sporadic single parathyroid adenoma.

1 May 2015

Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

There are two types of thyroid cells and therefore there are two broad types of thyroid cancer. Medullary carcinoma is derived from parafollicular or C cells, whereas follicular cells give rise to several types of thyroid cancers.

4 Feb 2015

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Incidence of thyroid cancer rising faster in Pennsylvania than in rest of the United States as a whole

Incidence of thyroid cancer is rising faster in Pennsylvania than in the rest of the United States as a whole, according to Penn State College of Medicine researchers.

11 Sep 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

Scientists discover new protein that drive metastasis of cancer cells

An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body.

11 Mar 2014

Principal investigators at Nationwide Children's Hospital elected as AAAS Fellows

Brian K. Kaspar, PhD, and Veronica J. Vieland, PhD, principal investigators in The Research Institute at Nationwide Children's Hospital, have been named Fellows of the American Association for the Advancement of Science (AAAS).

26 Nov 2013

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

A new analysis has found that the presence of short segments of genetic material (known as microRNA) within papillary thyroid cancer tumors suggests a likelihood of recurrence after patients undergo surgery.

29 Oct 2013

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

The American Thyroid Association (ATA) recommends against the routine use of radioactive iodine after surgery to remove the thyroid in patients with low-risk papillary thyroid cancer (PTC).

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Low-risk thyroid cancers are overdiagnosed and overtreated

An increasing gap between the incidence of thyroid cancer and deaths from the disease suggests that low-risk cancers are being overdiagnosed and overtreated, a study from the Mayo Clinic Center for the Science of Health Care Delivery finds. The study appears in the current issue of the British Medical Journal.

28 Aug 2013

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Late stage thyroid cancer patients with aggressive disease may benefit from a genetic test, but experts caution that use of this test in early stage patients is inappropriate because it is unlikely to lead to better outcomes.

11 Apr 2013

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

Radioactive iodine benefits selected papillary thyroid cancer patients

Radioactive iodine may be selectively used for the treatment of intermediate-risk papillary thyroid cancer in patients who are aged over 45 years with tumors smaller than 4 cm that are confined to the thyroid gland, say US scientists.

12 Dec 2012

Age 65 and above may be more accurate marker for prognosis of papillary thyroid cancer

Although age 45 is used to establish staging in well-differentiated papillary thyroid cancer using the American Joint Committee on Cancer and the International Union Against Cancer TNM Classification of Malignant Tumors (TNM) staging system, a new study presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada, suggests that > 65 may be a more accurate age marker for prognosis.

24 Sep 2012

Radioactive iodine should only be used in treatment of some patients with papillary thyroid cancer

Radioactive iodine should only be used in the treatment of some patients with papillary thyroid cancer, according to data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

Argentine President does not have cancer

Argentine President Cristina Fernandez had her thyroid gland removed amid fears of thyroid cancer. A detailed look at the tissues of her thyroid gland has shown no cancer authorities said Saturday.

9 Jan 2012

CLND may help reduce papillary thyroid cancer recurrence rates

Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women. A new study indicates that routinely removing lymph nodes in the neck in these cancer patients may help prevent the disease from coming back.

21 Dec 2011